PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

Pediatric Blood and Cancer

Volumn 60, Issue 9, 2013, Pages 1411-1417

  Skapek, Stephen X ^a   Anderson, James ^b   Barr, Frederic G ^c   Bridge, Julia A ^b   Gastier Foster, Julie M ^d   Parham, David M ^e   Rudzinski, Erin R ^f   Triche, Timothy ^g   Hawkins, Douglas S ^f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^f SEATTLE CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

PAX FOXO1; Rhabdomyosarcoma; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; PAIRED BOX TRANSCRIPTION FACTOR; TOPOTECAN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHILDHOOD CANCER; CONTROLLED STUDY; EMBRYONAL RHABDOMYOSARCOMA; EVENT FREE SURVIVAL; FUSION GENE; GENE EXPRESSION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; MULTIMODAL CHEMOTHERAPY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHABDOMYOSARCOMA;

PAX-FOXO1; RHABDOMYOSARCOMA; SURVIVAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PAX7 TRANSCRIPTION FACTOR; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; RISK FACTORS; SURVIVAL RATE;

EID: 84879431387     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24532     Document Type: Article

References (27)

1. Womer RB, Pressey JG. Rhabdomyosarcoma and soft tissue sarcoma in childhood. Curr Opin Oncol 2000; 12:337-344.
2. Merlino G, Helman LJ. Rhabdomyosarcoma-Working out the pathways. Oncogene 1999; 18:5340-5348.
3. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008; 26:2384-2389.
4. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's oncology group study D980. J Clin Oncol 2009; 27:5182-5188.
5. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 2001; 19:3091-3102.
6. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 3:113-117.
7. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 5:230-235.
8. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994; 54:2869-2872.
9. Slater O, Shipley J. Clinical relevance of molecular genetics to paediatric sarcomas. J Clin Pathol 2007; 60:1187-1194.
10. Williamson D, Missiaglia E, de RA, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010; 28:2151-2158.
11. Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma-Genotypic and phenotypic determinants of diagnosis. Am J Pathol 2009; 174:550-564.
12. Lae M, Ahn EH, Mercado GE, et al. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 2007; 212:143-151.
13. Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004; 64:5539-5545.
14. Barr FG, Smith LM, Lynch JC, et al. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: A report from the Children's Oncology Group. J Mol Diagn 2006; 8:202-208.
15. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol 2002; 20:2672-2679.
16. Davicioni E, Anderson JR, Buckley JD, et al. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: A report from the children's oncology group. J Clin Oncol 2010; 28:1240-1246.
17. Stegmaier S, Poremba C, Schaefer KL, et al. Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma study group (CWS). Pediatric Blood Cancer 2011; 57:406-414.
18. Missiaglia E, Williamson D, Chisholm J, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012; 30:1670-1677.
19. Rosenberg AR, Skapek SX, Hawkins DS. The inconvenience of convenience cohorts: Rhabdomyosarcoma and the PAX-FOXO1 biomarker. Cancer Epidemiol Biomarkers Prev 2012; 21:1012-1018.
20. Dumont SN, Lazar AJ, Bridge JA, et al. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. J Cancer Res Clin Oncol 2012; 138:213-220.
21. Anderson JR, Barr FG, Hawkins DS, et al. Fusion-negative alveolar rhabdomyosarcoma: Modification of risk stratification is premature. J Clin Oncol 2010; 28:e587-e588; author reply e589-590.
22. Spunt SL, Skapek SX, Coffin CM. Pediatric nonrhabdomyosarcoma soft tissue sarcomas. Oncologist 2008; 13:668-678.
23. Wexler LH, Ladanyi M. Diagnosing alveolar rhabdomyosarcoma: Morphology must be coupled with fusion confirmation. J Clin Oncol 2010; 28:2126-2128.
24. Barr FG, Duan F, Smith LM, et al. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group. Genes Chromosomes Cancer 2009; 48:661-672.
25. Reichek JL, Duan F, Smith LM, et al. Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group. Clin Cancer Res 2011; 17:1463-1473.
26. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26:317-325.
27. Sumegi J, Streblow R, Frayer RW, et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer 2010; 49:224-236.